Hussman Strategic Advisors Inc. Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hussman Strategic Advisors Inc. acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 2,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,496,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Nvwm LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.4% during the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock valued at $1,039,000 after acquiring an additional 14 shares during the last quarter. Westhampton Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Westhampton Capital LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $939,000 after acquiring an additional 15 shares during the last quarter. Howe & Rusling Inc. increased its position in Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Howe & Rusling Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 15 shares in the last quarter. Willner & Heller LLC increased its position in Regeneron Pharmaceuticals by 3.9% during the 4th quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 15 shares in the last quarter. Finally, OLD Second National Bank of Aurora increased its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company’s stock worth $2,025,000 after purchasing an additional 15 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $685.66 on Thursday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $74.96 billion, a P/E ratio of 17.91, a P/E/G ratio of 2.28 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock’s 50 day simple moving average is $700.92 and its 200 day simple moving average is $887.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 EPS. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research analyst reports. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Robert W. Baird dropped their target price on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Finally, Evercore ISI decreased their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.